Results 71 to 80 of about 59,126 (309)

Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease

Biomolecules, 2018
The mineralocorticoid receptor (MR) was first identified as a blood pressure regulator, modulating renal sodium handling in response to its principal ligand aldosterone.
Stefania Gorini, Vincenzo Marzolla, Caterina Mammi, Andrea Armani, Massimiliano Caprio   +4 more
doaj   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki, Tetsu Watanabe, Mari Shimizu, Shingo Tachibana, Junya Sato, Yuta Kobayashi, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source

A COMPARATIVE ASSESSMENT OF THE EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON CHANGES IN GALECTIN-3 AND MMP-1 FIBROSIS MARKERS IN PATIENTS WITH CHRONIC CARDIAC FAILURE COMBINED WITH TYPE 2 DIABETES MELLITUS WITH MANIFESTATIONS OF MYOCARDIUM DYSSYNCHRONY

Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016
A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj  

Localization of mineralocorticoid receptors at mammalian synapses. [PDF]

PLoS ONE, 2010
In the brain, membrane associated nongenomic steroid receptors can induce fast-acting responses to ion conductance and second messenger systems of neurons.
Eric M Prager, Jennifer Brielmaier, Hadley C Bergstrom, Jennifer McGuire, Luke R Johnson   +4 more
doaj   +1 more source

Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases [PDF]

, 2004
Fluticasone propionate - the first carbothioate corticosteroid - has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of ...
Atsuta J, Boner AL, Bridgman A, Callen J, Delescluse J, Dooms-Goossens AE, Dykes PJ, Falcoz C, Fisher DA, Goossens A, Harding SM, Hogger P, James M, Johnson M, Johnson M, Juhlin L, Katz HI, Korting HC, Lebwohl M, Li JT, Liu XQ, Llewellyn-Jones CG, Lucky AW, McKenzie AW, McLean HM, Nurnberger FG, Phillipps GH, Roberts DT, Spencer CM, Tharp MD, Venning VA, Wilkinson SM, Wolkerstorfer A, Young MMR   +33 more
core   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design [PDF]

, 2021
Isabella B. Stone, Jessica A.E.M. Green, Andrew W Koefoed, Ezra S. Hornik, Jonathan S. Williams, Gail K. Adler, Gordon H. Williams   +6 more
openalex   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source